Delivered mechanistic PoC in cirrhosis/HE Ph1b
Dosed over 100 patients in ongoing IBS trial. Delivered safety & efficacy data from IBS-C cohort
Delivering Ph2 trial in allo-HSCT in collaboration with Imperial College
Available data suggests that drug has robust safety and tolerability profile
Proprietary stabilising technology demonstrated at ambient temperature

Clinical pipeline